

# Index to Volume 31

## Index au volume 31

The *Journal of Psychiatry & Neuroscience* is indexed according to the medical subject headings established by the National Library of Medicine, US National Institutes of Health.

The title for each article is followed by a code that designates the article's category. The categories used in this volume are listed below.

La *Revue de psychiatrie & de neuroscience* est indexée par vedette-matière selon la nomenclature de la National Library of Medicine des National Institutes of Health américains.

Chaque titre d'article est suivi d'un code indiquant à quelle catégorie l'article appartient. Les catégories utilisées dans ce volume sont les suivantes :

Brief Report / Rapport sommaire (Brief)  
CCNP News and Views / Nouvelles et opinions du CCNP (CCNP)  
Commentary / Commentaire (Comm)  
Editorial / Éditorial (E)  
Letter / Lettre (L)  
Psychopharmacology for the Clinician / Psychopharmacologie pratique (Psychopharm)  
Research Paper / Article de recherche (Res)  
Review Paper / Examen critique (Rev)

### -A-

#### Abnormalities

Pregnancy, depression, antidepressants and breast-feeding (Blier) (E) 226

#### Adrenoceptors

The effect of lithium on the adrenoceptor-mediated second messenger system in the rat brain (Devaki and others) (Res) 246

#### Affect

Ecological momentary assessment: what it is and why it is a method of the future in clinical psychopharmacology (Moskowitz and Young) (E) 13

Social behaviour and mood in everyday life: the effects of tryptophan in quarrelsome individuals (aan het Rot and others) (Res) 253

#### Affective symptoms

Alexithymia and stress-induced brain activation in cocaine-dependent men and women (Li and Sinha) (Res) 115

#### Aggression

Social behaviour and mood in everyday life: the effects of tryptophan in quarrelsome individuals (aan het Rot and others) (Res) 253

#### Alcohol

Differential effects of naltrexone on cardiac, subjective and behavioural reactions to acute ethanol intoxication (Peterson and others) (Res) 386

#### Aldehyde load

Neurodegeneration and aldehyde load: from concept to therapeutics (Wood) (E) 296

#### Aldehyde sequestering agents

Neurodegeneration and aldehyde load: from concept to therapeutics (Wood) (E) 296

#### Alexithymia

Alexithymia and stress-induced brain activation in cocaine-dependent men and women (Li and Sinha) (Res) 115

#### Alzheimer disease

Managing discontinuation syndrome in patients with dementia (Gauthier) (Psychopharm) 72

Neurodegeneration and aldehyde load: from concept to therapeutics (Wood) (E) 296

#### Amyotrophic lateral sclerosis

Neurodegeneration and aldehyde load: from concept to therapeutics (Wood) (E) 296

#### Animal models

Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania (Frey and others) (Res) 326

The need for speed: an update on methamphetamine addiction (Barr and others) (Rev) 301

#### Anti-anxiety agents

The search for new off-label indications for antidepressant, antianxiety, antipsychotic and anticonvulsant drugs (Chouinard) (Rev) 168

#### Anticonvulsants

The search for new off-label indications for antidepressant, antianxiety, antipsychotic and anticonvulsant drugs (Chouinard) (Rev) 168

#### Antidepressants

Fluoxetine-induced alterations in human platelet serotonin transporter expression: serotonin transporter polymorphism effects (Little and others) (Res) 333

#### Antidepressive agents

Concerns regarding antidepressant use during pregnancy (Urato) (L) 411

Pregnancy, depression, antidepressants and breast-feeding (Blier) (E) 226

Reply: Practicing medicine on the basis of the unconfirmed and omitting the established facts (Blier) (L) 411

The search for new off-label indications for antidepressant, antianxiety, antipsychotic and anticonvulsant drugs (Chouinard) (Rev) 168

#### Antipsychotic agents

Antipsychotic drugs cause glial cell line-derived neurotrophic factor secretion from C6 glioma cells (Shao and others) (Res) 32

The "delayed onset" of antipsychotic action — an idea whose time has come and gone (Agid and others) (Rev) 93

Interrelations between psychiatric symptoms and drug-induced movement disorder (Chouinard) (Rev) 177

The search for new off-label indications for antidepressant, antianxiety, antipsychotic and anticonvulsant drugs (Chouinard) (Rev) 168

#### Antipsychotic medications

The rational use of medications in acute psychotic presentations — the case for less is more (Awad) (Psychopharm) 216

#### Anxiety

Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence (Dean and others) (Res) 38

#### Atomoxetine

Treating depression with selective norepinephrine reuptake inhibitors (Blier) (Psychopharm) 288

#### Attention deficit disorder with hyperactivity

Efficacy of methylphenidate in children with attention-deficit hyperactivity disorder and learning disabilities: a randomized crossover trial (Grizenko and others) (Res) 46

#### Attribution bias

About the mechanisms of auditory verbal hallucinations: a positron emission tomographic study (Stephane and others) (Res) 396

#### Atypical antipsychotic agents

Treatment guidelines for mania (Kennedy) (Psychopharm) 144

**Auditory verbal hallucinations (AVH)**

About the mechanisms of auditory verbal hallucinations: a positron emission tomographic study (Stephane and others) (Res) 396

**-B-****Biological psychiatry**

Fewer classes of drugs for more and more psychiatric disorders (Young) (E) 82

**Bipolar disorder**

The 29th Annual Meeting of the Canadian College of Neuro-psychopharmacology (Zawertailo and others) (CCNP) 413  
Downregulation in components of the mitochondrial electron transport chain in the postmortem frontal cortex of subjects with bipolar disorder (Sun and others) (Res) 189

Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania (Frey and others) (Res) 326

Increased olfactory sensitivity in euthymic patients with bipolar disorder with event-related episodes compared with patients with bipolar disorder without such episodes (Krüger and others) (Res) 263

Treatment guidelines for mania (Kennedy) (Psychopharm) 144

**Blotting**

Nuclear factor kappa B in the dorsal raphe of macaques: an anatomical link for steroids, cytokines and serotonin (Bethae and others) (Res) 105

**Borderline personality disorder**

"Missing links" in borderline personality disorder: loss of neural synchrony relates to lack of emotion regulation and impulse control (William and others) (Res) 181

**Brain**

The effect of lithium on the adrenoceptor-mediated second messenger system in the rat brain (Devaki and others) (Res) 246

"Missing links" in borderline personality disorder: loss of neural synchrony relates to lack of emotion regulation and impulse control (William and others) (Res) 181

**Brain imaging**

Brain imaging and cognitive dysfunctions in Huntington's disease (Montoya and others) (Rev) 21

**Brain imaging (MRI)**

The need for speed: an update on methamphetamine addiction (Barr and others) (Rev) 301

**Breast feeding**

Pregnancy, depression, antidepressants and breast-feeding (Blier) (E) 226

**Bupropion**

Psychopharmacology of smoking cessation in patients with mental illness (Selby) (Psychopharm) 360

**-C-****Cell death**

Antipsychotic drugs cause glial cell line-derived neurotrophic factor secretion from C6 glioma cells (Shao and others) (Res) 32

**Central nervous system**

The role of neurotensin in central nervous system pathophysiology: What is the evidence? (St-Gelais and others) (Rev) 229

**Chlorpromazine**

Levopromazine versus chlorpromazine in treatment-resistant schizophrenia: a double-blind randomized trial (Lal and others) (Res) 271

**Cholinesterase inhibitor**

Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy (Ferreri and others) (Rev) 369

**Clinical trials**

Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence (Dean and others) (Res) 38

Ecological momentary assessment: what it is and why it is a method of the future in clinical psychopharmacology (Moskowitz and Young) (E) 13

**Cocaine-related disorders**

Alexithymia and stress-induced brain activation in cocaine-dependent men and women (Li and Sinha) (Res) 115

**Cognition**

Brain imaging and cognitive dysfunctions in Huntington's disease (Montoya and others) (Rev) 21

Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy (Ferreri and others) (Rev) 369

"Missing links" in borderline personality disorder: loss of neural synchrony relates to lack of emotion regulation and impulse control (William and others) (Res) 181

**Corollary discharge, SMA**

About the mechanisms of auditory verbal hallucinations: a positron emission tomographic study (Stephane and others) (Res) 396

**Cyclic AMP**

The effect of lithium on the adrenoceptor-mediated second messenger system in the rat brain (Devaki and others) (Res) 246

**-D-****Dementia**

Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy (Ferreri and others) (Rev) 369

Managing discontinuation syndrome in patients with dementia (Gauthier) (Psychopharm) 72

The use of medroxyprogesterone acetate for the treatment of sexually inappropriate behaviour in patients with dementia (Light and Holroyd) (Brief) 132

**Depression**

Depression in acute stroke (Caeiro and others) (Res) 377

Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence (Dean and others) (Res) 38

Increased positive emotional memory after repetitive transcranial magnetic stimulation over the orbitofrontal cortex (Schutter and van Honk) (Res) 101

Is the thyroid still important in major depression? (Joffe) (E) 367

Metabolic syndrome: relevance to antidepressant treatment (Chokka and others) (Psychopharm) 414

Pregnancy, depression, antidepressants and breast-feeding (Blier) (E) 226

Reduced hippocampal volume correlates with executive dysfunctioning in major depression (Frodl and others) (Res) 316

Treating depression with selective norepinephrine reuptake inhibitors (Blier) (Psychopharm) 288

**Depressive disorder, major**

Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis (Kennedy and others) (Res) 122

The search for new off-label indications for antidepressant, antianxiety, antipsychotic and anticonvulsant drugs (Chouinard) (Rev) 168

**Diabetes**

Metabolic syndrome: relevance to antidepressant treatment (Chokka and others) (Psychopharm) 414

**Discontinuation**

Managing discontinuation syndrome in patients with dementia (Gauthier) (Psychopharm) 72

**Disinhibition**

The use of medroxyprogesterone acetate for the treatment of sexually inappropriate behaviour in patients with dementia (Light and Holroyd) (Brief) 132

**Donepezil**

Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy (Ferreri and others) (Rev) 369

Managing discontinuation syndrome in patients with dementia (Gauthier) (Psychopharm) 72

**Dopamine**

The 29th Annual Meeting of the Canadian College of Neuro-psychopharmacology (Zawertailo and others) (CCNP) 413

The rational use of medications in acute psychotic presentations — the case for less is more (Awad) (Psychopharm) 216

The role of neurotensin in central nervous system pathophysiology: What is the evidence? (St-Gelais and others) (Rev) 229

**Dopamine antagonists**

The “delayed onset” of antipsychotic action — an idea whose time has come and gone (Agid and others) (Rev) 93

**Dopaminergic system**

Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania (Frey and others) (Res) 326

**Drug therapy**

The “delayed onset” of antipsychotic action — an idea whose time has come and gone (Agid and others) (Rev) 93

**Dyskinesias**

Interrelations between psychiatric symptoms and drug-induced movement disorder (Chouinard) (Rev) 177

**Dystonia**

Interrelations between psychiatric symptoms and drug-induced movement disorder (Chouinard) (Rev) 177

**-E-****Electroencephalography**

“Missing links” in borderline personality disorder: loss of neural synchrony relates to lack of emotion regulation and impulse control (William and others) (Res) 181

**Electron transport**

Downregulation in components of the mitochondrial electron transport chain in the postmortem frontal cortex of subjects with bipolar disorder (Sun and others) (Res) 189

**Emotions**

Increased positive emotional memory after repetitive transcranial magnetic stimulation over the orbitofrontal cortex (Schutter and van Honk) (Res) 101

**Environment**

Schizophrenia: an integrative approach to modelling a complex disorder (Robertson and others) (Rev) 157

**Escitalopram**

Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis (Kennedy and others) (Res) 122

**Estrogen**

Nuclear factor kappa B in the dorsal raphe of macaques: an anatomical link for steroids, cytokines and serotonin (Bethea and others) (Res) 105

**Evoked potentials**

Increased olfactory sensitivity in euthymic patients with bipolar disorder with event-related episodes compared with patients with bipolar disorder without such episodes (Krüger and others) (Res) 263

**Executive memory**

Reduced hippocampal volume correlates with executive dysfunctioning in major depression (Frodl and others) (Res) 316

**Extrapyramidal symptoms**

Interrelations between psychiatric symptoms and drug-induced movement disorder (Chouinard) (Rev) 177

**-F-****Functional neuroimaging**

Brain imaging and cognitive dysfunctions in Huntington's disease (Montoya and others) (Rev) 21

**-G-****Gamma synchrony**

“Missing links” in borderline personality disorder: loss of neural synchrony relates to lack of emotion regulation and impulse control (William and others) (Res) 181

**Gene expression**

Fluoxetine-induced alterations in human platelet serotonin transporter expression: serotonin transporter polymorphism effects (Little and others) (Res) 333

**Genetics**

Downregulation in components of the mitochondrial electron transport chain in the postmortem frontal cortex of subjects with bipolar disorder (Sun and others) (Res) 189

Schizophrenia: an integrative approach to modelling a complex disorder (Robertson and others) (Rev) 157

**Glial cell line-derived neurotrophic factor**

Antipsychotic drugs cause glial cell line-derived neurotrophic factor secretion from C6 glioma cells (Shao and others) (Res) 32

**Glutamate**

The relation between peripheral and central glutamate and glutamine in healthy male volunteers (Shulman and others) (Brief) 406

**Glutamine**

The relation between peripheral and central glutamate and glutamine in healthy male volunteers (Shulman and others) (Brief) 406

**-H-****Haloperidol**

Levopromazine versus chlorpromazine in treatment-resistant schizophrenia: a double-blind randomized trial (Lal and others) (Res) 271

**Happiness**

Increased positive emotional memory after repetitive transcranial magnetic stimulation over the orbitofrontal cortex (Schutter and van Honk) (Res) 101

**Heart rate**

Differential effects of naltrexone on cardiac, subjective and behavioural reactions to acute ethanol intoxication (Peterson and others) (Res) 386

**Heroin dependence**

Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence (Dean and others) (Res) 38

**Hippocampus**

Reduced hippocampal volume correlates with executive dysfunctioning in major depression (Frodl and others) (Res) 316

**Huntington disease**

Brain imaging and cognitive dysfunctions in Huntington's disease (Montoya and others) (Rev) 21

**Hypertension**

Metabolic syndrome: relevance to antidepressant treatment (Chokka and others) (Psychopharm) 414

**-I-****Immunohistochemistry**

Nuclear factor kappa B in the dorsal raphe of macaques: an anatomical link for steroids, cytokines and serotonin (Bethea and others) (Res) 105

**Inositol-1,4,5-triphosphate (IP3)**

The effect of lithium on the adrenoceptor-mediated second messenger system in the rat brain (Devaki and others) (Res) 246

**Interpersonal relations**

Ecological momentary assessment: what it is and why it is a method of the future in clinical psychopharmacology (Moskowitz and Young) (E) 13

**-L-****Language**

A rant against jargon and neologisms (Young) (E) 155

**Learning disorders**

Efficacy of methylphenidate in children with attention-deficit hyperactivity disorder and learning disabilities: a randomized crossover trial (Grizenko and others) (Res) 46

**Levomepromazine**

Levomepromazine versus chlorpromazine in treatment-resistant schizophrenia: a double-blind randomized trial (Lal and others) (Res) 271

**Lexical processing**

About the mechanisms of auditory verbal hallucinations: a positron emission tomographic study (Stephane and others) (Res) 396

**Lithium**

The effect of lithium on the adrenoceptor-mediated second messenger system in the rat brain (Devaki and others) (Res) 246

Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania (Frey and others) (Res) 326

Downregulation in components of the mitochondrial electron transport chain in the postmortem frontal cortex of subjects with bipolar disorder (Sun and others) (Res) 189

Is the thyroid still important in major depression? (Joffe) (E) 367

**-M-****MADRS**

Depression in acute stroke (Caeiro and others) (Res) 377

**Magnetic resonance spectroscopy**

The relation between peripheral and central glutamate and glutamine in healthy male volunteers (Shulman and others) (Brief) 406

**Mania**

Treatment guidelines for mania (Kennedy) (Psychopharm) 144

**Medroxyprogesterone acetate**

The use of medroxyprogesterone acetate for the treatment of sexually inappropriate behaviour in patients with dementia (Light and Holroyd) (Brief) 132

**Memantine**

Managing discontinuation syndrome in patients with dementia (Gauthier) (Psychopharm) 72

**Memory**

Increased positive emotional memory after repetitive transcranial magnetic stimulation over the orbitofrontal cortex (Schutter and van Honk) (Res) 101

**Meta-analysis**

The 29th Annual Meeting of the Canadian College of Neuro-psychopharmacology (Zawertailo and others) (CCNP) 413

Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis (Kennedy and others) (Res) 122

**Metabolic syndrome**

Metabolic syndrome: relevance to antidepressant treatment (Chokka and others) (Psychopharm) 414

**Methadone**

Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence (Dean and others) (Res) 38

**Methamphetamine**

The need for speed: an update on methamphetamine addiction (Barr and others) (Rev) 301

**Methylphenidate**

Efficacy of methylphenidate in children with attention-deficit hyperactivity disorder and learning disabilities: a randomized crossover trial (Grizenko and others) (Res) 46

**Mitochondria**

Downregulation in components of the mitochondrial electron transport chain in the postmortem frontal cortex of subjects with bipolar disorder (Sun and others) (Res) 189

**Models, animal**

Antipsychotic drugs cause glial cell line-derived neurotrophic factor secretion from C6 glioma cells (Shao and others) (Res) 32

Schizophrenia: an integrative approach to modelling a complex disorder (Robertson and others) (Rev) 157

**Mood disorders**

Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence (Dean and others) (Res) 38

**Movement disorders**

Interrelations between psychiatric symptoms and drug-induced movement disorder (Chouinard) (Rev) 177

**-N-****Naltrexone**

Differential effects of naltrexone on cardiac, subjective and behavioural reactions to acute ethanol intoxication (Peterson and others) (Res) 386

Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence (Dean and others) (Res) 38

**Narcotic antagonists**

Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence (Dean and others) (Res) 38

**Neuroleptic dysphoria**

The rational use of medications in acute psychotic presentations — the case for less is more (Awad) (Psychopharm) 216

**Neurotensin**

The role of neurotensin in central nervous system pathophysiology: What is the evidence? (St-Gelais and others) (Rev) 229

**NF-kappa B**

Nuclear factor kappa B in the dorsal raphe of macaques: an anatomical link for steroids, cytokines and serotonin (Betha and others) (Res) 105

**Norepinephrine**

Treating depression with selective norepinephrine reuptake inhibitors (Bluer) (Psychopharm) 288

**-O-****Off-label indications**

The search for new off-label indications for antidepressant, antianxiety, antipsychotic and anticonvulsant drugs (Chouinard) (Rev) 168

**Orbitofrontal cortex**

Increased olfactory sensitivity in euthymic patients with bipolar disorder with event-related episodes compared with patients with bipolar disorder without such episodes (Krüger and others) (Res) 263

Increased positive emotional memory after repetitive transcranial magnetic stimulation over the orbitofrontal cortex (Schutter and van Honk) (Res) 101



**-P-****Parkinson disease**

- Neurodegeneration and aldehyde load: from concept to therapeutics (Wood) (E) 296
- The role of neurotensin in central nervous system pathophysiology: What is the evidence? (St-Gelais and others) (Rev) 229

**Parkinsonian disorders**

- Interrelations between psychiatric symptoms and drug-induced movement disorder (Chouinard) (Rev) 177

**Pathophysiology**

- The role of neurotensin in central nervous system pathophysiology: What is the evidence? (St-Gelais and others) (Rev) 229

**PET**

- About the mechanisms of auditory verbal hallucinations: a positron emission tomographic study (Stephane and others) (Res) 396

**Physiopathology**

- Fewer classes of drugs for more and more psychiatric disorders (Young) (E) 82

**Plasma**

- The relation between peripheral and central glutamate and glutamine in healthy male volunteers (Shulman and others) (Brief) 406

**Polymerase chain reaction**

- Downregulation in components of the mitochondrial electron transport chain in the postmortem frontal cortex of subjects with bipolar disorder (Sun and others) (Res) 189

**Prefrontal cortex**

- The relation between peripheral and central glutamate and glutamine in healthy male volunteers (Shulman and others) (Brief) 406

**Pregnancy**

- Concerns regarding antidepressant use during pregnancy (Urato) (L) 411
- Pregnancy, depression, antidepressants and breast-feeding (Blier) (E) 226
- Reply: Practicing medicine on the basis of the unconfirmed and omitting the established facts (Blier) (L) 411

**Pregnancy complications**

- Schizophrenia: an integrative approach to modelling a complex disorder (Robertson and others) (Rev) 157

**Progesterone**

- Nuclear factor kappa B in the dorsal raphe of macaques: an anatomical link for steroids, cytokines and serotonin (Bethea and others) (Res) 105

**Psychology, social**

- Ecological momentary assessment: what it is and why it is a method of the future in clinical psychopharmacology (Moskowitz and Young) (E) 13

**Psychopharmacology**

- Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania (Frey and others) (Res) 326
- Fewer classes of drugs for more and more psychiatric disorders (Young) (E) 82
- Psychopharmacology of smoking cessation in patients with mental illness (Selby) (Psychopharm) 360

**Psychoses**

- The need for speed: an update on methamphetamine addiction (Barr and others) (Rev) 301

**Publishing**

- A rant against jargon and neologisms (Young) (E) 155

**-Q-****QT-interval**

- Metabolic syndrome: relevance to antidepressant treatment (Chokka and others) (Psychopharm) 414

**-R-****Radioligand binding**

- The effect of lithium on the adrenoceptor-mediated second messenger system in the rat brain (Devaki and others) (Res) 246

**Rats**

- The effect of lithium on the adrenoceptor-mediated second messenger system in the rat brain (Devaki and others) (Res) 246

**Research**

- Ecological momentary assessment: what it is and why it is a method of the future in clinical psychopharmacology (Moskowitz and Young) (E) 13
- A rant against jargon and neologisms (Young) (E) 155

**Reuptake inhibitors**

- Treating depression with selective norepinephrine reuptake inhibitors (Blier) (Psychopharm) 288

**Reverse transcriptase polymerase chain reaction**

- Nuclear factor kappa B in the dorsal raphe of macaques: an anatomical link for steroids, cytokines and serotonin (Bethea and others) (Res) 105

**-S-****Safety**

- Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence (Dean and others) (Res) 38

**Schizoaffective disorders**

- Interrelations between psychiatric symptoms and drug-induced movement disorder (Chouinard) (Rev) 177

**Schizophrenia**

- About the mechanisms of auditory verbal hallucinations: a positron emission tomographic study (Stephane and others) (Res) 396
- Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy (Ferreri and others) (Rev) 369
- The "delayed onset" of antipsychotic action — an idea whose time has come and gone (Agid and others) (Rev) 93
- Interrelations between psychiatric symptoms and drug-induced movement disorder (Chouinard) (Rev) 177
- Levopromazine versus chlorpromazine in treatment-resistant schizophrenia: a double-blind randomized trial (Lal and others) (Res) 271
- The relation between peripheral and central glutamate and glutamine in healthy male volunteers (Shulman and others) (Brief) 406
- The role of neurotensin in central nervous system pathophysiology: What is the evidence? (St-Gelais and others) (Rev) 229
- Schizophrenia: an integrative approach to modelling a complex disorder (Robertson and others) (Rev) 157
- The search for new off-label indications for antidepressant, antianxiety, antipsychotic and anticonvulsant drugs (Chouinard) (Rev) 168

**Serotonergic mechanisms**

- Fluoxetine-induced alterations in human platelet serotonin transporter expression: serotonin transporter polymorphism effects (Little and others) (Res) 333

**Serotonin**

- Nuclear factor kappa B in the dorsal raphe of macaques: an anatomical link for steroids, cytokines and serotonin (Bethea and others) (Res) 105
- Social behaviour and mood in everyday life: the effects of tryptophan in quarrelsome individuals (aan het Rot and others) (Res) 253

**Serotonin uptake inhibitors**

Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis (Kennedy and others) (Res) 122

**Sexual disorder**

The use of medroxyprogesterone acetate for the treatment of sexually inappropriate behaviour in patients with dementia (Light and Holroyd) (Brief) 132

**Smell**

Increased olfactory sensitivity in euthymic patients with bipolar disorder with event-related episodes compared with patients with bipolar disorder without such episodes (Krüger and others) (Res) 263

**Smoking cessation**

Psychopharmacology of smoking cessation in patients with mental illness (Selby) (Psychopharm) 360

**Social behaviour**

Social behaviour and mood in everyday life: the effects of tryptophan in quarrelsome individuals (aan het Rot and others) (Res) 253

**Social perception**

Social behaviour and mood in everyday life: the effects of tryptophan in quarrelsome individuals (aan het Rot and others) (Res) 253

**SSRIs**

Concerns regarding antidepressant use during pregnancy (Urato) (L) 411

Reply: Practicing medicine on the basis of the unconfirmed and omitting the established facts (Blier) (L) 411

**Stimulant**

Differential effects of naltrexone on cardiac, subjective and behavioural reactions to acute ethanol intoxication (Peterson and others) (Res) 386

**Stroke, acute**

Depression in acute stroke (Caeiro and others) (Res) 377

**Structural MRI**

Reduced hippocampal volume correlates with executive dysfunctioning in major depression (Frodl and others) (Res) 316

**Structural neuroimaging**

Brain imaging and cognitive dysfunctions in Huntington's disease (Montoya and others) (Rev) 21

**Substance-related disorders**

Alexithymia and stress-induced brain activation in cocaine-dependent men and women (Li and Sinha) (Res) 115

**Substance use disorders**

The need for speed: an update on methamphetamine addiction (Barr and others) (Rev) 301

**-T-****Terminology**

A rant against jargon and neologisms (Young) (E) 155

**Therapeutics**

Fewer classes of drugs for more and more psychiatric disorders (Young) (E) 82

Transcranial magnetic stimulation, Increased positive emotional memory after repetitive transcranial magnetic stimulation over the orbitofrontal cortex (Schutter and van Honk) (Res) 101

**Thyroid**

Is the thyroid still important in major depression? (Joffe) (E) 367

**Treatment outcome**

Does naltrexone treatment lead to depression? Findings from a randomized controlled trial in subjects with opioid dependence (Dean and others) (Res) 38

Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis (Kennedy and others) (Res) 122

**Treatment resistance**

Levopromazine versus chlorpromazine in treatment-resistant schizophrenia: a double-blind randomized trial (Lal and others) (Res) 271

**Tricyclic antidepressants**

Metabolic syndrome: relevance to antidepressant treatment (Chokka and others) (Psychopharm) 414

**Tryptophan**

Social behaviour and mood in everyday life: the effects of tryptophan in quarrelsome individuals (aan het Rot and others) (Res) 253

**Author / Auteurs****-A-**

**aan het Rot M, Moskowitz DS, Pinard G, Young SN**

Social behaviour and mood in everyday life: the effects of tryptophan in quarrelsome individuals (Res) 253

**Agbokou C See Ferreri F Jt Auth**

**Agid O, Seeman P, Kapur S**

The "delayed onset" of antipsychotic action — an idea whose time has come and gone (Rev) 93

**Andersen HF See Kennedy SH Jt Auth**

**Annable L See Lal S Jt Auth**

**Awad AG**

The rational use of medications in acute psychotic presentations — the case for less is more (Psychopharm) 216

**-B-**

**Baker G See Shulman Y Jt Auth**

**Banac S See Frodl T Jt Auth**

**Bardini K See Frey BN Jt Auth**

**Barr AM, Panenka WJ, MacEwan GW, Thornton AE, Lang DJ, Honer WG, Lecomte T**

The need for speed: an update on methamphetamine addiction (Rev) 301

**Bethea CL, Reddy AP, Smith LJ**

Nuclear factor kappa B in the dorsal raphe of macaques: an anatomical link for steroids, cytokines and serotonin (Res) 105

**Bhat M See Grizenko N Jt Auth**

**Blier P**

Pregnancy, depression, antidepressants and breast-feeding (E) 226

Reply: Practicing medicine on the basis of the unconfirmed and omitting the established facts (L) 411

Treating depression with selective norepinephrine reuptake inhibitors (Psychopharm) 288

**Born C See Frodl T Jt Auth**

**Bottlender R See Frodl T Jt Auth**

**Bräunig P See Krüger S Jt Auth**

**-C-**

**Caeiro L, Ferro JM, Santos CO, Figueira ML**

Depression in acute stroke (Res) 377

**Casey KF See Zawertailo L Jt Auth**

**Charypar M See Frodl T Jt Auth**

**Chokka P, Tancer M, Yeragani VK**

Metabolic syndrome: relevance to antidepressant treatment (Psychopharm) 414

**Chouinard G**

Interrelations between psychiatric symptoms and drug-induced movement disorder (Rev) 177

The search for new off-label indications for antidepressant, antianxiety, antipsychotic and anticonvulsant drugs (Rev) 168

Christie BR See Ernst C Jt Auth  
 Connor JP See Dean AJ Jt Auth  
 Conrod P See Peterson JB Jt Auth  
 Cook E See Little KY Jt Auth

**-D-**

Dal-Pizzol F See Frey BN Jt Auth  
 Dean AJ, Saunders JB, Jones RT, Young RM, Connor JP, Lawford BR  
 Does naltrexone treatment lead to depression? Findings from a  
 randomized controlled trial in subjects with opioid  
 dependence (Res) 38  
 Devaki R, Shankar Rao S, Nadgir SM  
 The effect of lithium on the adrenoceptor-mediated second  
 messenger system in the rat brain (Res) 246  
 Dyck LE See Shao Z Jt Auth

**-E-**

Ernst C, Olson AK, Pinel JPJ, Lam RW, Christie BR  
 Antidepressant effects of exercise: Evidence for an adult-  
 neurogenesis hypothesis? (Rev) 84

**-F-**

Ferreri F, Agbokou C, Gauthier S  
 Cognitive dysfunctions in schizophrenia: potential benefits of  
 cholinesterase inhibitor adjunctive therapy (Rev) 369  
 Ferro JM See Caeiro L Jt Auth  
 Figueira ML See Caeiro L Jt Auth  
 Flores C See Zawertailo L Jt Auth  
 Frasnelli J See Krüger S Jt Auth  
 Frey BN, Valvassori SS, Réus GZ, Martins MR, Petronilho FC,  
 Bardini K, Dal-Pizzol F, Kapczinski F, Quevedo J  
 Effects of lithium and valproate on amphetamine-induced oxidative  
 stress generation in an animal model of mania (Res) 326  
 Frodl T, Schaub A, Banac S, Charypar M, Jäger M, Kümmler P,  
 Bottlender R, Zetzsche T, Born C, Leinsinger G, Reiser M,  
 Möller HJ, Meisenzal EM  
 Reduced hippocampal volume correlates with executive  
 dysfunctioning in major depression (Res) 316

**-G-**

Gabriel A See Lal S Jt Auth  
 Gauthier S  
 Managing discontinuation syndrome in patients with dementia  
 (Psychopharm) 72  
 Gauthier S See Ferreri F Jt Auth  
 Gianoulakis C See Peterson JB Jt Auth  
 Gordon E See Williams LM Jt Auth  
 Grant S See Shulman Y Jt Auth  
 Grizenko N, Bhat M, Schwartz G, Ter-Stepanian M, Joobar R  
 Efficacy of methylphenidate in children with attention-deficit  
 hyperactivity disorder and learning disabilities: a randomized  
 crossover trial (Res) 46

**-H-**

Hagen MC See Stephane M Jt Auth  
 Hanstock C See Shulman Y Jt Auth  
 Holroyd S See Light SA Jt Auth  
 Honer WG See Barr AM Jt Auth  
 Hori SE See Robertson GS Jt Auth  
 Hummel T See Krüger S Jt Auth

**-J-**

Jäger M See Frodl T Jt Auth  
 Joffe RT  
 Discontinuing treatment for psychiatric disorders (E) 11  
 Is the thyroid still important in major depression? (E) 367  
 Jomphe C See St-Gelais F Jt Auth  
 Jones RT See Dean AJ Jt Auth  
 Joobar R See Grizenko N Jt Auth

**-K-**

Kapczinski F See Frey BN Jt Auth  
 Kapur S See Agid O Jt Auth  
 Kennedy SH  
 Treatment guidelines for mania (Psychopharm) 144  
 Kennedy SH, Andersen HF, Lam RW  
 Efficacy of escitalopram in the treatment of major depressive  
 disorder compared with conventional selective serotonin  
 reuptake inhibitors and venlafaxine XR: a meta-analysis (Res) 122  
 Krüger S, Frasnelli J, Bräunig P, Hummel T  
 Increased olfactory sensitivity in euthymic patients with bipolar  
 disorder with event-related episodes compared with patients  
 with bipolar disorder without such episodes (Res) 263  
 Kümmler P See Frodl T Jt Auth  
 Kuskowski M See Stephane M Jt Auth

**-L-**

Lal S, Thavundayil JX, Nair NPV, Annable L, Ng Ying Kin NMK,  
 Gabriel A, Schwartz G  
 Levomepromazine versus chlorpromazine in treatment-resistant  
 schizophrenia: a double-blind randomized trial (Res) 271  
 Lam RW See Ernst C Jt Auth; Kennedy SH Jt Auth  
 Lang DJ See Barr AM Jt Auth  
 Lawford BR See Dean AJ Jt Auth  
 Lecomte T See Barr AM Jt Auth  
 Lee JT See Stephane M Jt Auth  
 Leinsinger G See Frodl T Jt Auth  
 Lepage M See Montoya A Jt Auth  
 Leyton M See Zawertailo L Jt Auth  
 Li CSR, Sinha R  
 Alexithymia and stress-induced brain activation in cocaine-  
 dependent men and women (Res) 115  
 Li XM See Shao Z Jt Auth  
 Light SA, Holroyd S  
 The use of medroxyprogesterone acetate for the treatment of  
 sexually inappropriate behaviour in patients with dementia  
 (Brief) 132  
 Little KY, Zhang L, Cook E  
 Fluoxetine-induced alterations in human platelet serotonin  
 transporter expression: serotonin transporter polymorphism  
 effects (Res) 333

**-M-**

MacEwan GW See Barr AM Jt Auth  
 Martins MR See Frey BN Jt Auth  
 Meares RA See Williams LM Jt Auth  
 Meisenzal EM See Frodl T Jt Auth  
 Menear M See Montoya A Jt Auth  
 Möller HJ See Frodl T Jt Auth  
 Montoya A, Price BH, Menear M, Lepage M  
 Brain imaging and cognitive dysfunctions in Huntington's  
 disease (Rev) 21  
 Moskowitz DS See aan het Rot M Jt Auth

**Moskowitz DS, Young SN**

Ecological momentary assessment: what it is and why it is a method of the future in clinical psychopharmacology (Comm) 13

**-N-**

**Nadgir SM** See Devaki R Jt Auth

**Nair NPV** See Lal S Jt Auth

**Ng Ying Kin NMK** See Lal S Jt Auth

**-O-**

**Olson AK** See Ernst C Jt Auth

**-P-**

**Panenka WJ** See Barr AM Jt Auth

**Pardo JV** See Stephane M Jt Auth

**Pardo PJ** See Stephane M Jt Auth

**Peterson JB, Conrod P, Vassileva J, Gianoulakis C, Pihl RO**

Differential effects of naltrexone on cardiac, subjective and behavioural reactions to acute ethanol intoxication (Res) 386

**Petronilho FC** See Frey BN Jt Auth

**Pihl RO** See Peterson JB Jt Auth

**Pinard G** See aan het Rot M Jt Auth

**Pinel JPJ** See Ernst C Jt Auth

**Powell KJ** See Robertson GS Jt Auth

**Price BH** See Montoya A Jt Auth

**-Q-**

**Quevedo J** See Frey BN Jt Auth

**-R-**

**Reddy AP** See Bethea CL Jt Auth

**Reiser M** See Frodl T Jt Auth

**Réus GZ** See Frey BN Jt Auth

**Robertson GS, Hori SE, Powell KJ**

Schizophrenia: an integrative approach to modelling a complex disorder (Rev) 157

**-S-**

**Santos CO** See Caeiro L Jt Auth

**Saunders JB** See Dean AJ Jt Auth

**Schaub A** See Fridl T Jt Auth

**Schutter DJLG, van Honk J**

Increased positive emotional memory after repetitive transcranial magnetic stimulation over the orbitofrontal cortex (Res) 101

**Schwartz G** See Grizenko N Jt Auth; Lal S Jt Auth

**Seeman P** See Agid O Jt Auth

**Selby P**

Psychopharmacology of smoking cessation in patients with mental illness (Psychopharm) 360

**Seres P** See Shulman Y Jt Auth

**Shankar Rao S** See Devaki R Jt Auth

**Shao Z, Dyck LE, Wang H, Li XM**

Antipsychotic drugs cause glial cell line-derived neurotrophic factor secretion from C6 glioma cells (Res) 32

**Shulman Y, Grant S, Seres P, Hanstock C, Baker G, Tibbo P**

The relation between peripheral and central glutamate and glutamine in healthy male volunteers (Brief) 406

**Sidis A** See Williams LM Jt Auth

**Sinha R** See Li CSR Jt Auth

**Smith LJ** See Bethea CL Jt Auth

**St-Gelais F, Jomphe C, Trudeau LÉ**

The role of neurotensin in central nervous system pathophysiology: What is the evidence? (Rev) 229

**Stephane M, Hagen MC, Lee JT, Uecker J, Pardo PJ, Kuskowski M, Pardo JV**

About the mechanisms of auditory verbal hallucinations: a positron emission tomographic study (Res) 396

**Sun X, Wang JF, Tseng M, Young LT**

Downregulation in components of the mitochondrial electron transport chain in the postmortem frontal cortex of subjects with bipolar disorder (Res) 189

**-T-**

**Tancer M** See Chokka P Jt Auth

**Ter-Stepanian M** See Grizenko N Jt Auth

**Thavundayil JX** See Lal S Jt Auth

**Thornton AE** See Barr AM Jt Auth

**Tibbo P** See Shulman Y Jt Auth

**Trudeau LÉ** See St-Gelais F Jt Auth

**Tseng M** See Sun X Jt Auth

**-U-**

**Uecker J** See Stephane M Jt Auth

**Urato AC**

Concerns regarding antidepressant use during pregnancy (L) 411

**-V-**

**Valvassori SS** See Frey BN Jt Auth

**van Honk J** See Schutter DJLG Jt Auth

**Vassileva J** See Peterson JB Jt Auth

**-W-**

**Wang H** See Shao Z Jt Auth

**Wang JF** See Sun X Jt Auth

**Williams LM, Sidis A, Gordon E, Meares RA**

"Missing links" in borderline personality disorder: loss of neural synchrony relates to lack of emotion regulation and impulse control (Res) 181

**Wood PL**

Neurodegeneration and aldehyde load: from concept to therapeutics (E) 296

**-Y-**

**Yeragani VK** See Chokka P Jt Auth

**Young LT**

Fewer classes of drugs for more and more psychiatric disorders (E) 82

**Young LT** See Sun X Jt Auth

**Young RM** See Dean AJ Jt Auth

**Young SN**

A rant against jargon and neologisms (E) 155

**Young SN** See aan het Rot M Jt Auth; Moskowitz DS Jt Auth

**-Z-**

**Zawertailo L, Casey KF, Leyton M, Flores C**

The 29th Annual Meeting of the Canadian College of Neuropsychopharmacology (CCNP) 413

**Zetzche T** See Frodl T Jt Auth

**Zhang L** See Little KY Jt Auth



## **Outside Back Cover**